A gene therapy trial for transfusion-dependent thalassaemia, an inherited blood disorder, gave positive...
- AACR 2018: SLFN11 predicts response to PARP inhibition in small cell lung cancer
- TaiwanJ’s JKB-121 falls victim to unexpected placebo response in NASH patients
- ILC 2018: NGM’s intravenous NASH therapy shows rapid reduction in liver fat content and fibrosis
- CD40 agonist developments could support Anti-PD-(L)1 therapy in pancreatic cancer
- ILC 2018: Allergan’s cenicriviroc shows continued fibrosis response in NASH patients in two year extended study
Gene therapy for beta-thalassaemia could eliminate need for transfusions
A gene therapy trial for transfusion-dependent thalassaemia, an inherited blood disorder, gave positive results in an interim analysis, with the majority of patients being transfusion-free following treatment.
Synlogic doses first subject in Phase I/IIa trial of SYNB1618
Synlogic has dosed the first subject in its Phase I/IIa clinical trial of SYNB1618, a Synthetic Biotic medicine being developed to treat phenylketonuria (PKU).
Summit Therapeutics ends dosing in PhaseOut DMD trial
Summit Therapeutics has completed patient dosing in the PhaseOut DMD clinical trial, a Phase II study of ezutromid to treat patients with duchenne muscular dystrophy (DMD), the most common and severe form of muscular dystrophy.
Qu Biologics to start Phase II trial of QBECO SSI to treat CD
Qu Biologics has received a ‘no objection letter’ (NOL) from Health Canada to commence a Phase II clinical trial of QBECO SSI for treatment of Crohn’s disease (CD).
AACR 2018: SLFN11 predicts response to PARP inhibition in small cell lung cancer
This year’s AACR meeting provided exciting preliminary data for additional therapeutic biomarkers in SCLC
TaiwanJ’s JKB-121 falls victim to unexpected placebo response in NASH patients
The future of TaiwanJ Pharmaceuticals’ JKB-121 as a NASH treatment is in jeopardy after it failed to demonstrate efficacy in a Phase II placebo-controlled trial, presented at the 2018 International Liver Congress (ILC) in Paris, France.
ILC 2018: NGM’s intravenous NASH therapy shows rapid reduction in liver fat content and fibrosis
Phase II efficacy data for NGM Biopharmaceuticals’ developmental non-alcoholic steatohepatitis (NASH) drug, NGM282, was presented at the 2018 International Liver Congress (ILC) in Paris, France.
Merck to begin two Phase III trials of PCV-15 (V114)
Merck is set to commence two new Phase III studies of PCV-15 (V114), an investigational polyvalent conjugate vaccine to prevent pneumococcal disease.
Fervent begins Phase IIa trial of FP-101 for vasomotor symptoms
Fervent Pharmaceuticals has initiated a Phase IIa clinical trial to investigate the therapeutic potential of FP-101 in treating vasomotor symptoms, including hot flashes, night sweats and insomnia, in post-menopausal women.
Asahi starts enrolment in Phase III trial of isavuconazole
Asahi Kasei Pharma has started enrolling patients in a Phase III trial of isavuconazole to treat deep-seated mycosis, comprised of invasive aspergillosis, chronic pulmonary aspergillosis, mucormycosis and cryptococcosis.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.